panobinostat

Ligand id: 7489

Name: panobinostat

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: panobinostat

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 3
Hydrogen bond donors 4
Rotatable bonds 8
Topological polar surface area 77.15
Molecular weight 349.18
XLogP 4.71
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Panobinostat was approved by the US FDA in February 2015 for the treatment of multiple myeloma. Panobinostat is being assessed in clinical trials as a treatment for various other forms of cancer, including several hematologic neoplasms, prostate and breast cancers, metastatic melanoma, non-small cell lung cancer and recurrent glioblastoma and as an anti-HIV therapy (NCT01680094). ClinicalTrials.gov hosts a list of registered clinical trials involving this compound.
Mechanism Of Action and Pharmacodynamic Effects
Inhibition of histone deacetylase enzymes by panobinostat is believed to cause apoptosis of malignant cells or slow the over-development of plasma cells in myeloma patients.